Biogen Appoints Monish Patolawala to its Board of Directors Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Monish Patolawala, currently President and Chief Financial Officer of 3M Company (“3M”), to the Company’s Board of Directors (the “Board”), effective January 1, 2024.…
Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy Novartis today announced positive topline results from the interim analysis of the ongoing pivotal Phase III ALIGN study (NCT04573478) of…
Phase III RUBY trial of Jemperli (dostarlimab) plus chemotherapy meets endpoint of overall survival in patients with primary advanced or recurrent endometrial cancer GSK plc today announced positive headline results from a planned analysis of Part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO…
CEPI and Moderna Harness mRNA Technology to Advance 100 Days Mission The Coalition for Epidemic Preparedness Innovations (CEPI) and Moderna, Inc. (NASDAQ:MRNA) have entered into a strategic partnership that will harness Moderna’s mRNA platform to accelerate the development of vaccines against viral…
Boehringer Ingelheim’s SPEVIGO wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award Boehringer Ingelheim today announced that SPEVIGO® (spesolimab) has been recognized as Best Orphan/Rare Diseases Solution of 2023 by the Galien Foundation. The Prix Galien USA Award was…
Immunis Chairman Dr. Hans Keirstead to Present at BIO Europe Conference in Germany Immunis, Inc., a private biotech pioneering cellular secretome treatments to address age and disease-related immune decline, proudly announces that its Chairman, Dr. Hans Keirstead, will present at BIO Europe in…
Imfinzi plus Lynparza reduced the risk of disease progression or death by 45% vs. chemotherapy in advanced or recurrent endometrial cancer Positive results from the primary analysis of the DUO-E Phase III trial showed that Imfinzi (durvalumab) plus platinum-based chemotherapy, followed by…
AMGEN PRESENTS NEW TARLATAMAB DATA IN SMALL CELL LUNG CANCER Amgen (NASDAQ:AMGN) today announced results from the global Phase 2 DeLLphi-301 study, evaluating tarlatamab, an investigational delta-like ligand 3 (DLL3) targeting BiTE® (bispecific T-cell engager) molecule, in patients with advanced stage small…
AMGEN TO WEBCAST INVESTOR CALL AT ESMO 2023 Amgen (NASDAQ:AMGN) today announced that it will host a webcasted call for the investment community at 8:00 a.m. ET on Tuesday, Oct. 24, 2023 following the presentation of new data from Amgen’s innovative oncology portfolio including AMG 193…
REGENERON BUILDS ON TOGETHER FOR CHANGE™ INITIATIVE WITH FIVE-YEAR, $5 MILLION COMMITMENT TO FUEL THE STEM TALENT PIPELINE IN NASHVILLE, TN TARRYTOWN, N.Y., Oct. 18, 2023 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a five-year, $5 million strategic investment to bolster Nashville, Tennessee’s science, technology,…
Takeda Settles Tax Dispute with Irish Revenue over Break Fee Received by Shire Takeda (TSE:4502/NYSE:TAK) today announced that it agreed with the Irish Revenue Commissioners (“Irish Revenue”) to settle a tax assessment related to the treatment of an acquisition break…
DePuy Synthes Receives FDA Clearance for TriLEAP™ Lower Extremity Anatomic Plating System Today, Johnson & Johnson MedTech* announced that DePuy Synthes, The Orthopaedics Company of Johnson & Johnson**, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA)…
